Simon Chauveau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Simon Chauveau has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Abdellatif Tazi
Université Paris Cité, Institut Cochin, UMR INSERM U1016-CNRS 8104, Phagocytes and Tumour Immunology Lab, Centre National des Référence des Histiocytoses, Service de Pneumologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
1 shared publication - Annick Clement
RaDiCo, Inserm, Trousseau Hospital, Paris, France
1 shared publication - Antoine Deschildre
Service de Pneumologie et d'Allergologie Pédiatrique Hôpital Jeanne de Flandre, Univ. Lille, CHU de Lille Lille France
1 shared publication - Antoine Dossier
Service de Médecine Interne, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, 75018 Paris, France
1 shared publication - Bahram Bodaghi
Sorbonne University, APHP, Pitié-Salpêtrière Hospital
1 shared publication - Catherine Chapelon-Abric
AP-HP Department of Internal Medicine and Clinical Immunology, La Pitié Salpétrière Hospital, AP-HP, 75013 Paris, France
1 shared publication
Latest Publications
- Open Access
- 3 July 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (7) , 2097
Child–Adult Transition in Sarcoidosis: A Series of 52 Patients
(1) Background: Pediatric sarcoidosis is a rare and mostly severe disease. Very few pediatric series with a prolonged follow-up are reported. We aimed to evaluate the evolution of pediatric sarcoidosis in adulthood. (2) Material and methods: Patients over 18-years-old with a pediatric-onset sarcoidosis (≤15-year-old) who completed at least a three-year follow-up in French expert centers were included. Clinical information at presentation and outcome in adulthood were studied. (3) Results: A total of 52 patients were included (34 prospectively in childhood and 18 retrospectively in adulthood), with a mean age of 12 (±2.7) at diagnosis. The median duration time of follow-up was 11.5 years (range 3–44.5). Relapses mostly occurred during treatment decrease (84.5%), others within the three years after treatment interruption (9.1%), and rarely when the disease was stable for more than three years (6.4%). Sarcoidosis was severe in 11 (21.2%) in adulthood. Patients received a high corticosteroid cumulative dose (median 17,900 mg) for a median duration of five years (range 0–32), resulting in mostly mild (18; 35.3%) and rarely severe (2; 3.8%) adverse events. (4) Conclusions: Pediatric-onset sarcoidosis needed a long-term treatment in almost half of the patients. Around one fifth of pediatric-onset sarcoidosis patients had severe sarcoidosis consequences in adulthood.
- 3 July 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (7) , 2097
Open AccessChild–Adult Transition in Sarcoidosis: A Series of 52 Patients
(1) Background: Pediatric sarcoidosis is a rare and mostly severe disease. Very few pediatric series with a prolonged follow-up are reported. We aimed to evaluate the evolution of pediatric sarcoidosis in adulthood. (2) Material and methods: Patients over 18-years-old with a pediatric-onset sarcoidosis (≤15-year-old) who completed at least a three-year follow-up in French expert centers were included. Clinical information at presentation and outcome in adulthood were studied. (3) Results: A total of 52 patients were included (34 prospectively in childhood and 18 retrospectively in adulthood), with a mean age of 12 (±2.7) at diagnosis. The median duration time of follow-up was 11.5 years (range 3–44.5). Relapses mostly occurred during treatment decrease (84.5%), others within the three years after treatment interruption (9.1%), and rarely when the disease was stable for more than three years (6.4%). Sarcoidosis was severe in 11 (21.2%) in adulthood. Patients received a high corticosteroid cumulative dose (median 17,900 mg) for a median duration of five years (range 0–32), resulting in mostly mild (18; 35.3%) and rarely severe (2; 3.8%) adverse events. (4) Conclusions: Pediatric-onset sarcoidosis needed a long-term treatment in almost half of the patients. Around one fifth of pediatric-onset sarcoidosis patients had severe sarcoidosis consequences in adulthood.